A randomized, double-blind, confirmatory study of VN-100 in healthy elderly volunteers

DAIICHISANKYO Co.,Ltd.0 个研究点目标入组 901 人开始时间: 2014年3月28日最近更新: 2023年10月17日

适应症

试验速览

阶段: 3 期
状态: 已完成
发起方
入组人数: 901

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

As a result of 1st intradermal vaccinated of VN-100 in healthy Japanese 65 years and older, seroconversion rate and GMT of HI antibody titer were confirmed to be good immunogenicity in any strain, and influenza HA vaccine non-inferiority for a 1st subcutaneous inoculation was verified. There were no serious safety problems in the safety of VN-100 group.

研究设计

研究类型: Interventional

入排标准

年龄范围: >= 65age old 至 ot applicable（—）
性别: All

入选标准

•Healthy elderly Japanese volunteers

排除标准

•1) Subjects with history of seasonal influenza in the past 6 months
•2) Subjects with history of seasonal influenza vaccination in the past 6 months

研究者

发起方

DAIICHISANKYO Co.,Ltd.

相似试验

已完成

1 期

VN-100 Ph1/2

JPRN-jRCT2080222050DAIICHISANKYO Co.,Ltd.600

已完成

3 期

Open study of quadrivalent VN-100 in Japanese healthy volunteersProphylaxis of influenza infection

JPRN-jRCT2080222562DAIICHISANKYO Co.,Ltd.150

已完成

1 期

V710 Clinical Study in Healthy Male Japanese Subjects (V710-006) (COMPLETED)Staphylococcal Infection

NCT00735839Merck Sharp & Dohme LLC40

已完成

1 期

Phase I/II clinical study of JVC-001Prevention of measles, mumps and rubella

JPRN-jRCT2080222978DAIICHI SANKYO Co.,Ltd.100

已完成

2 期

Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine M72/AS01E in Participants With Well-controlled HIVHuman Immunodeficiency Virus

NCT04556981Gates Medical Research Institute402